Skip to main content

Advertisement

SpringerLink
Log in

CIP2A expression and prognostic role in patients with esophageal adenocarcinoma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

CIP2A is overexpressed in many cancers, including esophageal squamous cell carcinoma. The regulation of c-MYC and CIP2A expression is characterized by a positive feedback mechanism facilitating the expression of both of them and accelerating cancer cell proliferation in gastric cancer. Increased CIP2A expression is a predictor of poor survival in some cancers. The incidence of positive CIP2A immunostaining and its association with c-MYC and its predictive value in esophageal adenocarcinoma are unknown. All esophageal adenocarcinoma patients from 1990 to 2007 with sufficient material for analysis of CIP2A and c-MYC in two university hospitals were included in the study. In addition, biopsies from Barrett’s epithelium from the cancer patients and control tissue from normal esophageal mucosa adjacent to the tumor were included. CIP2A was moderately or strongly positive in 77.9 %, and c-MYC in 93.8 % of the cancer specimens. These frequencies were statistically different from the expression in normal esophageal epithelium. In addition, there was a positive correlation between CIP2A and c-MYC expression (p = 0.018). According to adjusted Cox regression survival analysis, CIP2A and c-MYC had no effect on survival. However, among patients with stage IVA–IVB cancer, there was a trend toward poor prognosis in CIP2A-positive patients. The expression of CIP2A and c-MYC was associated with each other, and their overexpression was found in most cases of esophageal adenocarcinoma. However, CIP2A and c-MYC had no effect on survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Sihvo E, Salminen J, Rämö O, Salo J. The epidemiology of oesophageal adenocarcinoma: has the cancer of gastric cardia an influence on the rising incidence of oesophageal adenocarcinoma? Scand J Gastroenterol. 2000;35:1082–6.

    Article  PubMed  CAS  Google Scholar 

  2. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–31.

    Article  PubMed  CAS  Google Scholar 

  3. Ye W, Chow W, Lagergren J, Yin L, Nyren O. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux disease and after antireflux surgery. Gastroenterology. 2001;12:1286–93.

    Article  Google Scholar 

  4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.

    Article  PubMed  CAS  Google Scholar 

  5. Arnold HK, Sears RC. Protein phosphatase 2A regulatory subunit B56alpha associates with c-MYC and negatively regulates c-MYC accumulation. Mol Cell Biol. 2006;26:2832–44.

    Article  PubMed  CAS  Google Scholar 

  6. Junttila MR, Puustinen P, Niemelä M, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007;130:51–62.

    Article  PubMed  CAS  Google Scholar 

  7. Katz J, Jakymiw A, Ducksworth M, Stewart C, Bhattacharyya I, Cha S, Chan E. CIP 2A expression and localization in oral carcinoma and dysplasia. Cancer Biol Ther. 2010;107:694–9.

    Google Scholar 

  8. Böckelman C, Hagström J, Mäkinen LK, et al. High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer. Br J Cancer. 2011;104:1890–5.

    Article  PubMed  Google Scholar 

  9. Qu W, Li W, Wei L, Xing L, Wang X, Yu J. CIP2A is overexpressed in esophageal squamous cell carcinoma. Med Oncol. 2012;29:113–8.

    Article  PubMed  Google Scholar 

  10. Khanna A, Böckelman C, Hemmes A, et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst. 2009;101:793–805.

    Article  PubMed  CAS  Google Scholar 

  11. Li W, Ge Z, Liu C, Liu Z, Björkholm M, Jia J, Xu D. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res. 2008;14:3722–8.

    Article  PubMed  CAS  Google Scholar 

  12. Grady W, Markowitz S. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet. 2002;3:101–28.

    Article  PubMed  CAS  Google Scholar 

  13. Teng H, Yang S, Lin J, et al. CIP2A is a predictor of poor prognosis in colon cancer. J Gastrointest Surg. 2012;16:1037–47.

    Article  PubMed  Google Scholar 

  14. Dong Q, Wang Y, Dong X, Li Z, Tang Z, Cui Q, Wang E. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol. 2011;18:857–65.

    Article  PubMed  Google Scholar 

  15. Xu P, Xu X, Huang Q, Zhang Z, Zhang Y. CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis. Med Oncol. 2012;29:1643–7.

    Article  PubMed  CAS  Google Scholar 

  16. Liang M, Zhe-Sheng W, Zi L, et al. Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer. PLoS One. 2011;5:1–10.

    Google Scholar 

  17. Vaarala M, Väisänen M, Ristimäki A. CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res. 2010;29:136.

    Article  PubMed  Google Scholar 

  18. Ren J, Li W, Yan L, et al. Expression of CIP2A in renal cell carcinomas correlates with tumor invasion, metastasis and patients’ survival. Br J Cancer. 2011;105:1905–11.

    Article  PubMed  CAS  Google Scholar 

  19. Böckelman C, Lassus H, Hemmes A, et al. Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer. 2011;105:989–95.

    Article  PubMed  Google Scholar 

  20. Huang L, Adelson M, Mordechai E, Trama J. CIP2A expression is elevated in cervical cancer. Cancer Biomark. 2010;8:309–17.

    PubMed  CAS  Google Scholar 

  21. Come C, Laine A, Chanrion M, et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res. 2009;15:5092–100.

    Article  PubMed  CAS  Google Scholar 

  22. Sarbia M, Arjumand J, Wolter M, Reifenberger G, Heep H, Gabbert H. Frequent c-MYC amplification in high-grade dysplasia and adenocarcinoma in Barrett esophagus. Am J Clin Pathol. 2001;115:835–40.

    Article  PubMed  CAS  Google Scholar 

  23. Tselepis C, Morris C, Wakelin D, et al. Upregulation of the oncogene c-MYC in Barrett’s adenocarcinoma: induction of c-MYC by acidified bile acid in vitro. Gut. 2003;52:174–80.

    Article  PubMed  CAS  Google Scholar 

  24. Schmidt M, Meurer L, Volkweis B, Edelweiss M, Schirmer C, Kruel C, Gurski R. c-MYC overexpression is strongly associated with metaplasia–dysplasia–adenocarcinoma sequence in the esophagus. Dis Esophagus. 2007;20:212–6.

    Article  PubMed  CAS  Google Scholar 

  25. Lucas C, Harris R, Giannoudis A, Copland M, Slupsky J, Clark R. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood. 2011;24:6660–8.

    Article  Google Scholar 

  26. Sihvo E, Luostarinen M, Salo J. Fate of patients with adenocarcinoma of the esophagus and the esophagogastric junction: a population-based analysis. Am J Gastroenterol. 2004;99:419–24.

    Article  PubMed  Google Scholar 

  27. Rice T, Blackstone E, Rusch V. 7th edition of the AJCC cancer staging manual: esophagus and esophagogastric junction. Ann Surg Oncol. 2010;17:1721–4.

    Article  PubMed  Google Scholar 

  28. Bosman F, Carneiro F, Hruban R, Theise N. WHO classification of tumors of the digestive systems. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2010.

    Google Scholar 

  29. Böckelman C, Koskensalo S, Hagström J, Lundin M, Ristimäki A, Haglund C. CIKP2A overexpression is associated with c-MYC expression in colorectal cancer. Cancer Biol Ther. 2012;5:289–95.

    Google Scholar 

Download references

Acknowledgments

The present study was funded by competitive research funding of Tampere University Hospital, Seinäjoki Central Hospital and Helsinki University Hospital. In addition, the study was financially supported by the legacy fund of E. K. Savolainen.

Conflict of interest

There are no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Surgery, Central Hospital of Seinäjoki, Hanneksenrinne 7, 60220, Seinäjoki, Finland

    Tuomo Rantanen

  2. Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland

    Tuomo Rantanen

  3. Clinic of General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland

    Tuuli Kauttu & Jarmo Salo

  4. Department of Pathology, School of Medicine, University of Tampere, Tampere, Finland

    Jonne Åkerla, Teemu Honkanen & Timo Paavonen

  5. Department of Pathology, Fimlab Laboratories, Tampere University Hospital, Tampere, Finland

    Teemu Honkanen & Timo Paavonen

  6. Department of Pathology, Helsinki University Hospital, Helsinki, Finland

    Leena Krogerus

  7. Division of Vascular Surgery, Department of Surgery, Tampere University Hospital, Tampere, Finland

    Niku Oksala

Authors
  1. Tuomo Rantanen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tuuli Kauttu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jonne Åkerla
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Teemu Honkanen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Leena Krogerus
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jarmo Salo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Timo Paavonen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Niku Oksala
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tuomo Rantanen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rantanen, T., Kauttu, T., Åkerla, J. et al. CIP2A expression and prognostic role in patients with esophageal adenocarcinoma. Med Oncol 30, 684 (2013). https://doi.org/10.1007/s12032-013-0684-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-013-0684-7

Keywords

Search

Navigation